Table 2.
Demographics and clinical characteristics of non-renal SLE patients in cross-sectional study.
| Active non-renal SLE (n=18) | Non-renal SLE in remission (n=35) | P value | |
|---|---|---|---|
| Age (year) | 50.61 ± 9.00 | 46.60 ± 10.80 | 0.195 |
| Gender (F: M) | 15:3 | 31:4 | 0.678 |
| a Duration of SLE (y) | 20.00 (15.00, 26.00) | 13.00 (7.00, 22.00) | 0.031 |
| SLEDAI-2K score | 5.56 ± 3.45 | 2.63 ± 2.49 | 0.001 |
| Serum anti-dsDNA antibody (IU/ml) | 98.22 ± 72.96 | 57.68 ± 64.78 | 0.020 |
| Serum C3 (mg/dl) | 82.94 ± 22.00 | 81.94 ± 21.88 | 0.842 |
| Prednisolone dose (mg/day) | 14.17 ± 8.36 | 6.71 ± 3.81 | <0.0001 |
| Clinical manifestations during flare: | |||
| Arthritis | 4 | ||
| Vasculitis | 4 | ||
| Thrombocytopenia | 7 | ||
| Leukopenia | 3 |
Results expressed as mean ± SD.
a
Duration of SLE expressed as median (25 and 75% percentile).